Diatrizoate Meglumine And Diatrizoate Sodium

Diatrizoate Meglumine is a high-osmolarity, ionic iodinated contrast agent used primarily for the radiologic examination of the gastrointestinal tract and various vascular structures. It belongs to the class of organic iodine compounds that enhance X-ray visualization.

The dosage of Diatrizoate Meglumine is highly individualized and depends on the specific procedure, the patient's body weight, and the imaging equipment used.

• Oral Administration for GI Tract: For a standard adult examination of the upper gastrointestinal tract, the usual dose is 30 mL to 90 mL of a solution containing approximately 37% iodine. For CT scans of the abdomen, the solution is often diluted (e.g., 30 mL of concentrate mixed with 1,000 mL of water or juice) to prevent 'streak artifacts' caused by too much contrast.
• Rectal Administration (Enema): For visualization of the colon, 240 mL of a diluted solution is typically administered.
• Intravenous Urography: The standard adult dose is 30 mL to 60 mL of a 60% or 76% solution, injected rapidly into a vein.
• Angiography: Doses vary widely; for example, cerebral angiography may require 8 mL to 12 mL per injection, while aortography may require 40 mL to 60 mL.

Pediatric dosing must be calculated with extreme care, usually based on the child's weight and age.

• Oral/Rectal: For infants and children, the dose is generally 15 mL to 30 mL of a diluted solution. For very small infants, a dilution of 1 part contrast to 3 parts water is often recommended to reduce the risk of dehydration due to the high osmolarity (salt concentration) of the drug.
• Intravenous: The typical dose for excretory urography in children is 0.5 mL to 1 mL per pound of body weight, not to exceed the adult maximum.

Renal Impairment

In patients with pre-existing kidney disease (Creatinine Clearance < 60 mL/min), the risk of contrast-induced nephropathy (CIN) is significantly increased. Healthcare providers may reduce the dose, use a non-ionic (lower risk) agent instead, or ensure the patient is aggressively hydrated with IV fluids before and after the procedure.

Hepatic Impairment

No specific dose adjustments are generally required for patients with liver disease, as the drug is primarily excreted by the kidneys. However, patients with combined renal and hepatic failure are at the highest risk for toxicity.

Elderly Patients

Older adults often have age-related declines in kidney function and are more susceptible to dehydration. Providers typically use the lowest effective dose and monitor hydration status closely.

• Preparation: If taking the medication orally for a CT scan, you may be asked to drink the solution in stages (e.g., half two hours before the scan and the rest 30 minutes before).
• Fasting: Patients are often required to fast (nothing to eat or drink) for several hours before the procedure to ensure the stomach is empty and to reduce the risk of nausea.
• Hydration: It is vital to drink plenty of water before and after receiving Diatrizoate Meglumine to help the kidneys flush the iodine out of your system.
• Storage: The solution should be stored at room temperature (20°C to 25°C) and protected from light. If crystals form, the solution can be warmed gently until they disappear.

Since Diatrizoate Meglumine is typically administered by a healthcare professional in a clinical setting for a specific scheduled procedure, a missed dose is unlikely. If you miss your imaging appointment, contact your doctor immediately to reschedule. Do not attempt to take the contrast agent at home unless specifically instructed for a pre-procedure preparation.

An overdose of Diatrizoate Meglumine is a medical emergency, primarily affecting the kidneys and the cardiovascular system. Signs of overdose may include:

• Severe nausea and vomiting
• Rapid or irregular heartbeat
• Difficulty breathing
• Sudden decrease in urine output (kidney failure)
• Seizures or confusion

In the event of an overdose, treatment is supportive and may involve intensive IV hydration, monitoring of electrolytes, and in severe cases, hemodialysis to remove the contrast from the blood.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or preparation method without medical guidance.

Most patients experience mild, transient reactions during or immediately after the administration of Diatrizoate Meglumine. These are often related to the high osmolarity of the solution.

• Warmth or Flushing: A sudden sensation of heat throughout the body, particularly common during rapid intravenous injection. This usually lasts less than a minute.
• Metallic Taste: A temporary change in taste perception during or after injection.
• Nausea: A feeling of sickness in the stomach, which usually resolves quickly without treatment.
• Diarrhea (Oral use): Because the solution is highly concentrated, it can draw water into the intestines, causing loose stools shortly after ingestion.

Diatrizoate Meglumine must only be administered under the supervision of a physician experienced in the use of contrast agents. Because of the risk of severe allergic reactions, the facility must be equipped with emergency supplies (epinephrine, oxygen, IV fluids) and staff trained in advanced cardiac life support.

No FDA black box warnings for Diatrizoate Meglumine.

• Allergic Reactions / Anaphylaxis Risk: Patients with a history of asthma, hay fever, or food allergies are at a higher risk for a reaction. A 'test dose' is generally not recommended, as it does not reliably predict whether a severe reaction will occur during the full dose.
• Nephrotoxicity (Kidney Damage)

There are no absolute drug-drug contraindications where use is strictly forbidden, but certain combinations require extreme caution.

• Intrathecal Administration: Diatrizoate Meglumine must NEVER be injected into the spinal canal (intrathecally). This can cause severe neurotoxicity, including seizures, paralysis, and death.

• Metformin: In patients with impaired kidney function, the use of contrast agents can lead to lactic acidosis (a dangerous buildup of acid in the blood) if the contrast causes kidney failure. Most guidelines recommend stopping metformin at the time of the procedure and withholding it for 48 hours until kidney function is confirmed to be normal.
• Nephrotoxic Drugs: Medications that can damage the kidneys, such as NSAIDs (ibuprofen, naproxen), aminoglycoside antibiotics (gentamicin), and certain antiviral drugs, should be avoided or used with extreme caution around the time of contrast administration to prevent cumulative kidney injury.

• Known Hypersensitivity to Diatrizoate Salts: Patients who have had a previous severe or anaphylactic reaction to Diatrizoate Meglumine or Diatrizoate Sodium must not receive it again. The risk of a repeat, potentially fatal reaction is extremely high.
• Intrathecal Use: As mentioned previously, this drug is not formulated for injection into the spine.
• Significant Dehydration: In patients who are severely dehydrated, the high osmolarity of the drug can cause further fluid shifts and acute renal failure. Dehydration must be corrected before administration.

These are conditions where the benefit of the imaging must be carefully weighed against the risks:

Diatrizoate Meglumine is classified as Pregnancy Category B (or C depending on the specific manufacturer and route). Animal studies have not shown a risk to the fetus, but there are no adequate, well-controlled studies in pregnant women. Iodine is known to cross the placenta and can potentially affect the fetal thyroid gland. Therefore, its use during pregnancy should be limited to cases where the diagnostic benefit clearly outweighs the potential risks to the fetus.

Diatrizoate Meglumine is excreted in human milk in very small amounts. Furthermore, the drug is poorly absorbed from the infant's gastrointestinal tract. According to the American College of Radiology (ACR), breastfeeding can usually be continued normally after receiving iodinated contrast. However, some cautious clinicians suggest expressing and discarding milk for 24 hours after the procedure if the mother is concerned.

Diatrizoate Meglumine is FDA-approved for use in children for various imaging procedures. However, infants (especially neonates) are at high risk for electrolyte imbalances and dehydration due to the high osmolarity of the solution. Doses must be carefully calculated, and the solution is almost always diluted for oral or rectal use in young children.

Diatrizoate Meglumine is a triiodinated, ionic, high-osmolar contrast medium (HOCM). Its molecular structure consists of a benzene ring with three iodine atoms at positions 2, 4, and 6. These iodine atoms provide the necessary radiopacity. The 'meglumine' part is a cation (positively charged ion) that increases the solubility of the diatrizoate molecule in water. When X-rays pass through the body, the iodine atoms absorb the radiation via the photoelectric effect, preventing the X-rays from reaching the film or detector, thus appearing white or 'opaque' on the resulting image.

Diatrizoate Meglumine is pharmacologically inert at diagnostic doses, meaning it does not trigger biological responses through receptor binding. Its effects are purely physical. The duration of the contrast effect depends on the route: for GI imaging, it lasts as long as the material is present in the gut; for IV urography, the peak 'nephrogram' (kidney image) occurs within 1-3 minutes of injection.

| Parameter | Value |

|---|---|